Hormone treatment for postmenopausal women and its effects on Alzheimer's disease
Official title: Hormone Replacement Trial Against ALzheimers' Disease
Run by University Hospital, Ghent · NCT04312399 · Data updated 2026-11-12
This study tests if hormone replacement therapy can help postmenopausal women, with or without a history of breast cancer, by looking at its effects on dementia and Alzheimer's disease.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 40 Years to 65 Years |
| Sex | Women only |
| Enrollment | 600 (estimated) |
| Sponsor | University Hospital, Ghent Academic / other |
| Locations | 1 site (Ghent) |
| Status | Recruiting |
| Started | April 17, 2018 |
| Main results expected | December 31, 2027 |
| Study ends | December 31, 2028 |
| Registry record updated | January 27, 2025 |
| Trial ID | NCT04312399 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are postmenopausal women aged 40 to 65.
✕Probably not a fit
Patients who have been in menopause for longer than 10 years or have a history of certain medical conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This trial investigates the effects of hormone replacement therapy on dementia in postmenopausal women. It aims to analyze the degradation products of amyloid in the cerebrospinal fluid and blood to understand the relationship between menopause and the onset of Alzheimer's disease. Participants will include postmenopausal women aged 40 to 65, both with and without a history of breast cancer. The study will involve blood sample collection to assess metabolic changes associated with hormonal therapy.
Why it matters
Potential benefit: If successful, this study could provide insights into how hormone replacement therapy may influence the risk or progression of Alzheimer's disease in postmenopausal women.
How similar studies have gone: While the relationship between hormone therapy and Alzheimer's disease is being explored, this specific approach focusing on postmenopausal women and amyloid degradation products is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * postmenopausal women * 40 - 65 years Exclusion Criteria: * Longer than 10 years in menopause * thyroid dysfunction * hypertension * medical history of psychiatric comorbidity * Alcohol and/or drug abuse * medical history of neurologic symptoms with cognitive symptoms
Where it's running
-
Ghent university hospital
Ghent, Belgium Recruiting
Study contacts
- Principal investigator: Herman Depypere, MD — University Hospital, Ghent
- Study coordinator: Eline Meireson, Msc
- Email: eline.meireson@uzgent.be
- Phone: 0032 9 332 78 17
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Blood biomarker cohort for memory disorders in older adults
This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.
-
Tau changes after hip or knee replacement surgery
Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.
-
Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Mild Alzheimer's Dementia
This study will test whether a low-dose brain radiation treatment using HeLaXON helps people with mild Alzheimer's dementia improve or stabilize thinking and daily function.
-
Cervical lymphatic surgery to see if it helps people with mild Alzheimer’s
We’re testing a surgical approach in people with mild Alzheimer’s to see if creating alternative neck lymph drainage routes can affect brain biomarkers and daily function.
-
Transcranial random noise stimulation for behavioral and psychological symptoms in Alzheimer's disease
This trial tests whether high-frequency transcranial random noise stimulation can help people with early Alzheimer's disease who have BPSD, compared to a sham treatment.
-
Testing LY4405094 in healthy people and people with Alzheimer’s disease
This study tests LY4405094 to see if it is safe and how it behaves in the body, including how it reaches the brain fluid in healthy participants and how it affects a brain protein in people with Alzheimer's disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.